TRIAL TWO RAPAMYCIN STUDY FORM
The phase 2 rapamycin intervention study is planned to be a long-term study to evaluate the benefits of rapamycin on healthy aging in pet dogs. This study is intended to last 3-5 years and will hopefully begin enrollment during 2016, pending funding.
At this time, there are no restrictions on geographic location. We expect this study to include dogs from around the United States and, perhaps, the rest of the world. There are no restrictions on breed of dog for the phase 2 study. Dogs must be at least 6 years old, 40 pounds in weight minimum and in good health, without significant pre-existing conditions.
Dogs selected for this study will receive a low dose of rapamycin and be evaluated through regular veterinary exams and activities with their owners. Several age-associated traits will be followed including cognitive function, cardiac function, immunity, and cancer incidence.
Based on laboratory studies, we anticipate that this regimen of rapamycin treatment could improve healthy longevity of typical pet dogs by 2-5 years.
If you would like to register your interest in participating in the phase 2 rapamycin study, please complete the questionnaire below.